8-K: Bionano Genomics Announces $3 Million Registered Direct Offering Priced At-the-Market

Bionano Genomics has entered into a definitive agreement for a registered direct offering to raise approximately $3 million through the sale of common stock and warrants.

Summary

• Bionano Genomics has agreed to sell 9,881,113 shares of common stock, along with Series C and Series D warrants, in a registered direct offering.
• The combined offering price is $0.3039 per share and accompanying warrants.
• The Series C warrants expire five years after stockholder approval, while the Series D warrants expire after eighteen months.
• The company expects to receive approximately $3 million in gross proceeds from the offering, with potential additional gross proceeds of $6 million if the warrants are fully exercised for cash.
• The net proceeds will be used for general corporate purposes, including working capital, research and development, debt repayment, and capital expenditures.
• The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.

Sentiment

Score: 4

Explanation: The document indicates a necessary capital raise, which is a negative signal. While the company secures funding, it also dilutes existing shareholders and relies on future warrant exercises for additional capital. The company's financial position is not strong, requiring additional financing to continue operations.

Positives

• The offering provides Bionano Genomics with additional capital for general corporate purposes.
• The potential for an additional $6 million in gross proceeds from warrant exercises could further strengthen the company's financial position.
• The offering is priced at-the-market, which is consistent with Nasdaq rules.

Negatives

• The offering involves the issuance of a significant number of new shares, which could dilute existing shareholders.
• The company's ability to receive the additional $6 million is contingent on the warrants being exercised, which is not guaranteed.
• The company is relying on additional financing to fund its strategic plans and commercialization efforts.

Risks

• The company's ability to receive the additional $6 million is contingent on the warrants being exercised, which is not guaranteed.
• The company's ability to continue as a going concern requires it to manage costs and obtain significant additional financing.
• The company faces challenges inherent in developing, manufacturing, and commercializing products.
• The company's ability to further deploy new products and applications and expand the markets for its technology platforms is uncertain.
• The company's ability to cure any deficiencies in compliance with Nasdaq Listing Rules could adversely affect its ability to raise capital.
• The company may seek relief under applicable insolvency laws if it fails to obtain additional financing.

Future Outlook

The company intends to use the net proceeds for general corporate purposes, including working capital, research and development, debt repayment, and capital expenditures. The company's future financial performance is dependent on its ability to manage costs, obtain additional financing, and successfully commercialize its products.

Management Comments

• The company intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and available-for-sale securities, for general corporate purposes, including working capital, research and development expenses, repayment or redemption of existing indebtedness and capital expenditures.

Industry Context

This offering is a common method for biotech companies to raise capital, especially those in the development stage. The use of warrants is a way to attract investors, offering potential future upside. The company's focus on genome analysis solutions aligns with the growing interest in personalized medicine and genetic research.

Comparison to Industry Standards

• The use of registered direct offerings is a common practice for companies like Bionano Genomics to raise capital.
• The pricing of the offering at-the-market is consistent with industry standards for such transactions.
• The inclusion of warrants is a typical incentive for investors in these types of offerings, similar to other biotech companies seeking funding.
• The potential for additional capital through warrant exercises is a common feature in biotech financings, providing a potential future benefit to the company.
• Comparable companies in the biotech space, such as Pacific Biosciences and Oxford Nanopore, have also utilized similar financing methods to fund their operations and research.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Investors who purchase the securities will have the potential for future gains if the company performs well and the warrants are exercised.
• Employees may benefit from the company's ability to continue operations and fund research and development.
• Creditors may benefit from the company's ability to repay or redeem existing indebtedness.

Next Steps

• The company will seek stockholder approval for the issuance of shares upon exercise of the warrants.
• The company will use the net proceeds for general corporate purposes, including working capital, research and development, debt repayment, and capital expenditures.
• The company will file a final prospectus supplement with the SEC.

Key Dates

Keywords

registered direct offering, common stock, warrants, capital raise, Bionano Genomics, stockholder approval, H.C. Wainwright & Co., dilution, financing